Comment from Henk van der Poel: TKI is currently standard of care in advanced renal cancer. In particular in clear cell cancers responses are impressive, delay in progression substantial, improvement in overall survival noticeable albeit without complete responses. TKI are not without toxicity. In this registry 198/833 (24%) of patients stopped treatment because of toxicity over a median of 4.4 months. Increased age and number of metastases as well as decreased renal function were among the stongest predictors of treatment cessation.
Comment from Henk van der Poel: In metastasized sarcomatoid renal cell cancer median overall survival is half that of non-sarcomatoid cancers. Although response to VEGF inhibition is diminished in sarcomatoid cancers, 21% still had an objective response but primary refractory disease is twice as common as in non-sarcomatoid renal cancers.
Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre
URO ONCO is made possible by an unrestricted educational grant from:
The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.
The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views.